MCID: LKM002
MIFTS: 72

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 44 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia is related to acute leukemia and childhood leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 77 Leukemia, also spelled leukaemia, is a group of blood cancers that usually begin in the bone marrow and... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1778)
# Related Disease Score Top Affiliating Genes
1 acute leukemia 34.5 CEBPA ETV6 FLT3 RUNX1
2 childhood leukemia 34.5 ABL1 ETV6 PBX1 RUNX1
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.4 ETV6 FLT3 RUNX1
4 leukemia, acute lymphoblastic 34.4 ABL1 BCR ETV6 FLT3 MIR27A RUNX1
5 acute myeloblastic leukemia without maturation 34.4 FLT3 NPM1
6 acute myeloblastic leukemia with maturation 34.4 FLT3 NPM1
7 chronic myelomonocytic leukemia 34.3 ETV6 FLT3 RUNX1
8 cytogenetically normal acute myeloid leukemia 34.3 CEBPA FLT3 NPM1
9 core binding factor acute myeloid leukemia 34.3 CEBPA FLT3 RUNX1
10 myeloid leukemia 34.3 ABL1 BCR CEBPA ETV6 FLT3 LIF
11 leukemia, chronic myeloid 34.2 ABL1 BCR ETV6 FLT3 HOTAIR RUNX1
12 b-cell childhood acute lymphoblastic leukemia 34.1 ETV6 RUNX1
13 lymphoid leukemia 34.0 ETV6 FLT3
14 lymphocytic leukemia 34.0 BCR ETV6 HOTAIR RUNX1
15 leukemia, acute lymphoblastic 3 33.9 ABL1 BCR ETV6 FLT3 PBX1 RUNX1
16 acute lymphocytic leukemia 33.9 BCR CDKN2B-AS1 ETV6 RUNX1
17 b-cell adult acute lymphocytic leukemia 33.9 ABL1 PBX1
18 aleukemic leukemia cutis 33.9 FLT3 NPM1 RUNX1
19 precursor t-cell acute lymphoblastic leukemia 33.9 ABL1 BCR ETV6 FLT3 TCL1A
20 acute promyelocytic leukemia 33.8 CEBPA FLT3 HOTAIRM1 NEAT1 NPM1 PML
21 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.8 CEBPA FLT3 RUNX1
22 philadelphia-negative chronic myeloid leukemia 33.7 ABL1 BCR
23 platelet disorder, familial, with associated myeloid malignancy 33.4 ETV6 RUNX1
24 myelodysplastic syndrome 33.0 ABL1 CEBPA ETV6 FLT3 MLF1 NPM1
25 8p11 myeloproliferative syndrome 32.7 BCR FLT3 RUNX1
26 leukemia, acute myeloid 32.5 ABL1 BCR CDKN2B-AS1 CEBPA ETV6 FLT3
27 bone marrow cancer 31.0 ABL1 BCR ETV6 FLT3 RUNX1
28 hematologic cancer 29.9 ABL1 BCR ETV6 FLT3 NPM1 RUNX1
29 cerebral meningioma 29.6 LIF LIFR
30 kidney cancer 29.2 GAS5 HOTAIR MIR27A
31 thyroid cancer, nonmedullary, 1 28.8 GAS5 HOTAIR NEAT1
32 melanoma 28.8 CDKN2B-AS1 GAS5 HOTAIR HOTAIRM1 MIR27A
33 glioma 28.8 CDKN2B-AS1 GAS5 HOTAIR NEAT1
34 osteogenic sarcoma 28.7 CDKN2B-AS1 GAS5 HOTAIR NEAT1
35 thyroid cancer 28.6 CDKN2B-AS1 GAS5 HOTAIR MLF1 NEAT1
36 nasopharyngeal carcinoma 28.4 CDKN2B-AS1 GAS5 HOTAIR NEAT1
37 malignant glioma 28.4 CDKN2B-AS1 GAS5 HOTAIR NEAT1
38 oral squamous cell carcinoma 28.1 HOTAIR MIR27A NEAT1
39 leukemia, chronic lymphocytic 12.7
40 hairy cell leukemia 12.5
41 juvenile myelomonocytic leukemia 12.5
42 megakaryocytic leukemia 12.5
43 leukemia, acute monocytic 12.5
44 t-cell prolymphocytic leukemia 12.5
45 adult t-cell leukemia 12.5
46 acute lymphoblastic leukemia, childhood 12.4
47 acute monoblastic leukemia 12.4
48 monocytic leukemia 12.4
49 prolymphocytic leukemia 12.4
50 pdgfrb-associated chronic eosinophilic leukemia 12.4

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 ABL1 BCR CEBPA ETV6 FLT3 LIF
2 hematopoietic system MP:0005397 10.15 ABL1 BCR CEBPA ETV6 FLT3 LIF
3 growth/size/body region MP:0005378 10.14 ABL1 BCR CEBPA ETV6 FLT3 LIF
4 endocrine/exocrine gland MP:0005379 10.13 ABL1 CEBPA ETV6 FLT3 LIF LIFR
5 immune system MP:0005387 10.1 ABL1 BCR CEBPA ETV6 FLT3 LIF
6 embryo MP:0005380 10.06 ABL1 ETV6 LIF LIFR NPM1 PBX1
7 mortality/aging MP:0010768 9.93 ABL1 BCR CEBPA ETV6 FLT3 LIF
8 liver/biliary system MP:0005370 9.91 ABL1 BCR CEBPA LIF LIFR NPM1
9 neoplasm MP:0002006 9.5 CEBPA ETV6 FLT3 NPM1 PML RAF1
10 normal MP:0002873 9.23 ABL1 BCR CEBPA ETV6 PBX1 PML

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Arranon 19 50 NELARABINE GlaxoSmithKline October 2005
2
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
3
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
4
Blincyto 19 50 BLINATUMOMAB Amgen December 2014
5
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
6
Busulfex 19 50 BUSULFAN Orphan Medical February 1999
7
Campath 19 50 ALEMTUZUMAB Berlex Laboratories May 2001
8
Clolar 19 50 CLOFARABINE Genzyme December, 2004
9
Elitek 19 50 RASBURICASE sanofi-aventis October 2009
10
Elliotts B Solution 19 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
11
Erwinaze 19 50 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
12
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
13
Gleevec 19 50 IMATINIB MESYLATE Novartis May 2001
14
Iclusig 19 50 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
15
Imbruvica 19 50 IBRUTINIB Pharmacyclics November of 2013/February 2014
16
Intron A 19 50 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
17
Leukine 19 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
18
Marqibo 19 50 VINCRISTINE SULFATE Talon Therapeutics August 2012
19
Mylotarg 19 50 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
20
Neupogen 19 50 FILGRASTIM Amgen Approval April 1998
21
Revlimid 19 50 LENALIDOMIDE Celgene June 2013
22
Sprycel 19 50 DASATINIB Bristol-Myers Squibb June 2006
23
Synribo 19 50 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
24
Tasigna 19 50 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
25
Treanda 19 50 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
26
Trisenox 19 50 ARSENIC TRIOXIDE Cell Therapeutics September 2000
27
Zydelig 19 50 IDELALISIB Gilead July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1032)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
3
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
4
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1327-53-3 518740
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
9
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
10
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
11
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53910-25-1 439693 40926
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
15
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
16
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
17
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
18
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
19
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
20
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
22
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
23
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
24
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
25
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
26
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
27
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
28
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
29
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
30
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4291-63-8 20279
31
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
32
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53643-48-4, 59917-39-4 40839
33
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
34
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
35
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 172673-20-0 219090
36
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 6918365 151165
37
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
38
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
40
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
41
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
42
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
43
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 305-03-3 2708
44
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
45
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
46
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
47
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
48
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
49
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
50
ofatumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 679818-59-8 6918251

Interventional clinical trials:

(show top 50) (show all 6733)
# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
3 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
4 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
6 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
10 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
11 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
12 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
13 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
14 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
15 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
16 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
17 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
18 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
19 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
20 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
21 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
22 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
23 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
24 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
25 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
26 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
27 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
28 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
29 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
30 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
31 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
32 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
33 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
34 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
35 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
36 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
37 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
38 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
39 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
40 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
41 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
42 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
43 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
44 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
45 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
46 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
47 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
48 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
49 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
50 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 30

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

42
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Breast

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 55230)
# Title Authors Year
1
Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia. ( 31029024 )
2019
2
Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax. ( 31106622 )
2019
3
Acute basophilic leukemia with U2AF1 mutation. ( 30827760 )
2019
4
The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models. ( 30668984 )
2019
5
Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation. ( 30771495 )
2019
6
Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia. ( 30614357 )
2019
7
Early Deaths in Pediatric Acute Leukemia: A Major Challenge in Developing Countries. ( 30615014 )
2019
8
Therapeutic granulocyte transfusions: neutropenic patients with acute leukemia continue to need them - why are definitive evidence-based practice guidelines elusive? ( 30615809 )
2019
9
Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndromes in Adolescents and Young Adults Compared with Children: A Multicenter Study. ( 30625391 )
2019
10
Challenges in Clinical Metaproteomics Highlighted by the Analysis of Acute Leukemia Patients with Gut Colonization by Multidrug-Resistant Enterobacteriaceae. ( 30626002 )
2019
11
Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study. ( 30626352 )
2019
12
Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. ( 30626574 )
2019
13
Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status. ( 30639430 )
2019
14
Bloodstream infection (BSI) due to Vancomycin-Resistant Enterococcus (VRE) is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: A multicenter, retrospective cohort study. ( 30649224 )
2019
15
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. ( 30651113 )
2019
16
Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia. ( 30655374 )
2019
17
Mathematical models of amino acid panel for assisting diagnosis of children acute leukemia. ( 30674317 )
2019
18
Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. ( 30702467 )
2019
19
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. ( 30707502 )
2019
20
Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells. ( 30733302 )
2019
21
Long Non-Coding RNA and Acute Leukemia. ( 30744139 )
2019
22
Analytical performance of automated platelet counts and impact on platelet transfusion guidance in patients with acute leukemia. ( 30761915 )
2019
23
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. ( 30786841 )
2019
24
'Acute leukemia in congenital methehemoglobinemia - an enigma to explore'. ( 30788079 )
2019
25
Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of EBMT acute leukemia Working Party. ( 30792203 )
2019
26
Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study. ( 30824955 )
2019
27
Audit of Quality and Quantity of Nucleic Acid Yield from Pediatric Acute Leukemia Cases Following a Bio-banking Initiative. ( 30828152 )
2019
28
Mixed Phenotype Acute Leukemia, B/Myeloid with t(9;22): Diagnostic and Therapeutic Challenges. ( 30828170 )
2019
29
Psychosocial Experiences of Young Adults Diagnosed With Acute Leukemia During Hospitalization for Induction Chemotherapy Treatment. ( 30829935 )
2019
30
Correction to: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. ( 30836977 )
2019
31
Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia. ( 30844749 )
2019
32
Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience. ( 30858955 )
2019
33
ATP-Binding Cassette transporters' gene expression in pediatric patients with acute leukemia; a comprehensive analysis of published reports through PubMed search engine. ( 30860475 )
2019
34
Acute leukemia in a patient with 15q overgrowth syndrome. ( 30861314 )
2019
35
Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization. ( 30863166 )
2019
36
Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. ( 30863527 )
2019
37
High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS). ( 30864117 )
2019
38
Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged. ( 30872272 )
2019
39
Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. ( 30880638 )
2019
40
Ophthalmic Manifestations of Acute Leukemia. ( 30891378 )
2019
41
Association between NAT2 polymorphisms and acute leukemia risk: A meta-analysis. ( 30896661 )
2019
42
Staging of acute leukemia based on central nervous system involvement alone: Is it appropriate? ( 30900807 )
2019
43
Nasal embryonal rhabdomyosarcoma with bone marrow metastasis simulating acute leukemia: A case report and review of the literature. ( 30902383 )
2019
44
Treatment of venous thromboembolism in acute leukemia: A systematic review. ( 30921533 )
2019
45
Xiao W, Bharadwaj M, Levine M, et al. PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood Adv. 2018;2(23):3526-3539. ( 30926597 )
2019
46
Can allogeneic hematopoietic cell transplant cure therapy-related acute leukemia? ( 30927969 )
2019
47
A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. ( 30932944 )
2019
48
Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. ( 30952616 )
2019
49
Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (2017) 1303-1310]. ( 30953638 )
2019
50
Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 1939-1947]. ( 30954498 )
2019